Valeo Financial Advisors’s Vir Biotechnology VIR Stock Holding History

Valeo Financial Advisors’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10	Closed	–	–	1862
2020 Q3	$0	Buy	+10	New	+$431	﹤0.01%	2146

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Valeo Financial Advisors's VIR Position: Q4 2020 in Review

Valeo Financial Advisors sold out of Vir Biotechnology (VIR) in Q4 2020, closing a stake of 10 shares.

Valeo Financial Advisors first reported a position in VIR in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 143 funds tracked by Wall St. Rank hold VIR as of Q4 2020.

Valeo Financial Advisors reported no remaining Vir Biotechnology position as of Q4 2020 after selling out during the quarter.
Valeo Financial Advisors sold 10 Vir Biotechnology shares in Q4 2020.
Valeo Financial Advisors first reported a position in Vir Biotechnology in Q3 2020 and held it in 1 quarter.
Valeo Financial Advisors's Vir Biotechnology position peaked at $0 in Q3 2020.
143 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2020.

Based on Valeo Financial Advisors's 13F filing for Q4 2020, filed 11 Feb 2021.